Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-06

AUTHORS

E. Barrett-Connor, S. W. Wade, T. P. Do, S. Satram-Hoang, R. Stewart, G. Gao, D. Macarios

ABSTRACT

Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up. More... »

PAGES

733-741

References to SciGraph publications

  • 2005-03-03. Correlation between patient recall of bone densitometry results and subsequent treatment adherence in OSTEOPOROSIS INTERNATIONAL
  • 2005-04. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study in AGING CLINICAL AND EXPERIMENTAL RESEARCH
  • 2006-03-15. Determinants of adherence to osteoporosis treatment in clinical practice in OSTEOPOROSIS INTERNATIONAL
  • 2009-12-05. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis in OSTEOPOROSIS INTERNATIONAL
  • 2009-06-05. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review in OSTEOPOROSIS INTERNATIONAL
  • 2008-07-08. Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications in OSTEOPOROSIS INTERNATIONAL
  • 2009-08-06. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass in OSTEOPOROSIS INTERNATIONAL
  • 2006-08-01. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey in OSTEOPOROSIS INTERNATIONAL
  • 2010-01-26. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ in OSTEOPOROSIS INTERNATIONAL
  • 2008-09-12. Patient Decision to Initiate Therapy for Osteoporosis: The Influence of Knowledge and Beliefs in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2004-02-26. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2003-03. Tolerability and compliance with risedronate in clinical practice in OSTEOPOROSIS INTERNATIONAL
  • 2009-12-10. Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice in TRIALS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3

    DOI

    http://dx.doi.org/10.1007/s00198-011-1620-3

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1049583566

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/21625886


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bone Density Conservation Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diphosphonates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Epidemiologic Methods", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Medication Adherence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Osteoporosis, Postmenopausal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Osteoporotic Fractures", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Patient Satisfaction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Primary Health Care", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United States", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.266100.3", 
              "name": [
                "Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Barrett-Connor", 
            "givenName": "E.", 
            "id": "sg:person.01346631166.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346631166.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Wade Outcomes Research and Consulting, Salt Lake City, UT, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Wade Outcomes Research and Consulting, Salt Lake City, UT, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wade", 
            "givenName": "S. W.", 
            "id": "sg:person.0617012057.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Do", 
            "givenName": "T. P.", 
            "id": "sg:person.0733051777.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Satram-Hoang", 
            "givenName": "S.", 
            "id": "sg:person.01262457746.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262457746.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stewart", 
            "givenName": "R.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gao", 
            "givenName": "G.", 
            "id": "sg:person.01151363702.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151363702.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Macarios", 
            "givenName": "D.", 
            "id": "sg:person.0652405653.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652405653.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00198-002-1370-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021711183", 
              "https://doi.org/10.1007/s00198-002-1370-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1745-6215-10-113", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051078892", 
              "https://doi.org/10.1186/1745-6215-10-113"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-008-0674-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041206509", 
              "https://doi.org/10.1007/s00198-008-0674-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-0976-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025143605", 
              "https://doi.org/10.1007/s00198-009-0976-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03324587", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038551591", 
              "https://doi.org/10.1007/bf03324587"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11606-008-0772-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029719812", 
              "https://doi.org/10.1007/s11606-008-0772-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-004-1818-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019683703", 
              "https://doi.org/10.1007/s00198-004-1818-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-006-0166-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034510225", 
              "https://doi.org/10.1007/s00198-006-0166-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1134-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021804673", 
              "https://doi.org/10.1007/s00198-009-1134-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1023-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034744843", 
              "https://doi.org/10.1007/s00198-009-1023-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-006-0073-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020337646", 
              "https://doi.org/10.1007/s00198-006-0073-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00198-009-1133-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042711530", 
              "https://doi.org/10.1007/s00198-009-1133-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1477-7525-2-12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039428500", 
              "https://doi.org/10.1186/1477-7525-2-12"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2011-04-06", 
        "datePublishedReg": "2011-04-06", 
        "description": "Women in POSSIBLE US\u2122 who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US\u2122) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n\u2009=\u20091,182; median\u2009=\u200987.5 (Q1\u2009=\u200975.0, Q3\u2009=\u2009100.0)] and lowest for global satisfaction [n\u2009=\u20092,340; median\u2009=\u200964.0 (Q1\u2009=\u200955.7, Q3\u2009=\u200977.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI\u2009=\u20090.63\u20130.85; effectiveness 0.82, 95% CI\u2009=\u20090.70\u20130.97; and global satisfaction 0.73, 95% CI\u2009=\u20090.63\u20130.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR\u2009=\u20090.60, 95% CI\u2009=\u20090.37\u20130.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1\u00a0year of follow-up.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00198-011-1620-3", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1100834", 
            "issn": [
              "0937-941X", 
              "1433-2965"
            ], 
            "name": "Osteoporosis International", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "keywords": [
          "treatment satisfaction", 
          "severe side effects", 
          "discontinuation/", 
          "osteoporosis medications", 
          "side effects", 
          "hazard ratio", 
          "study entry", 
          "Prospective Observational Scientific Study", 
          "osteoporosis medication adherence", 
          "discontinuation/switching", 
          "global satisfaction domains", 
          "side effect severity", 
          "Treatment Satisfaction Questionnaire", 
          "lower treatment satisfaction", 
          "proportional hazards regression", 
          "greater treatment satisfaction", 
          "longitudinal cohort study", 
          "patient-reported data", 
          "TSQM scores", 
          "postmenopausal women", 
          "cohort study", 
          "osteoporosis therapy", 
          "medication adherence", 
          "hazards regression", 
          "lifestyle behaviors", 
          "medications", 
          "effect severity", 
          "logistic regression", 
          "median score", 
          "satisfaction questionnaire", 
          "satisfaction domains", 
          "women", 
          "global satisfaction", 
          "high satisfaction", 
          "scores", 
          "lower scores", 
          "risk", 
          "lower satisfaction", 
          "association", 
          "bisphosphonates", 
          "regression", 
          "MethodsData", 
          "satisfaction", 
          "therapy", 
          "follow", 
          "experience study", 
          "severity", 
          "adherence", 
          "study", 
          "period", 
          "effect", 
          "questionnaire", 
          "entry", 
          "participants", 
          "compliance", 
          "years", 
          "scientific studies", 
          "persistence", 
          "uses", 
          "possible uses", 
          "data", 
          "relationship", 
          "ratio", 
          "results", 
          "instruction", 
          "domain", 
          "behavior", 
          "switching"
        ], 
        "name": "Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US\u2122", 
        "pagination": "733-741", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1049583566"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00198-011-1620-3"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "21625886"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00198-011-1620-3", 
          "https://app.dimensions.ai/details/publication/pub.1049583566"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-20T07:27", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_552.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00198-011-1620-3"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1620-3'


     

    This table displays all metadata directly associated to this object as RDF triples.

    285 TRIPLES      22 PREDICATES      121 URIs      100 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00198-011-1620-3 schema:about N03c4ecfa1018472da54b6ea79dd15670
    2 N0ebcf9e1f4e741a1811d4431b13b9313
    3 N269e2e5ffd3747718a7a65f32857a4ba
    4 N2f456adc52694788a76261f2a94b1bb5
    5 N45cfa34dba0d4594bf27fc8e4e82b80f
    6 N63ec79ec89b9494babd25b711978c3d3
    7 N6eb32962c01b4e1f819323db0744cdb9
    8 Na9bb60b9411e4dd79ddd04d80630f743
    9 Nb7bab3fef41844bf8b82e1ac14a5a3dd
    10 Nc392fd3d8504459db709ffb07a890b75
    11 Ncb2bcd660c874831950e0f9a413e28ad
    12 Nd1dd8dac6391443eaec3bd0b32896807
    13 Nd5d59f5afb4845b58e70b75c4ff9015b
    14 Ndffff3838d504e5bb68d681e2269ab44
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N6422f536099f4c93b17f4f9bb5973d26
    18 schema:citation sg:pub.10.1007/bf03324587
    19 sg:pub.10.1007/s00198-002-1370-3
    20 sg:pub.10.1007/s00198-004-1818-8
    21 sg:pub.10.1007/s00198-006-0073-6
    22 sg:pub.10.1007/s00198-006-0166-2
    23 sg:pub.10.1007/s00198-008-0674-3
    24 sg:pub.10.1007/s00198-009-0976-0
    25 sg:pub.10.1007/s00198-009-1023-x
    26 sg:pub.10.1007/s00198-009-1133-5
    27 sg:pub.10.1007/s00198-009-1134-4
    28 sg:pub.10.1007/s11606-008-0772-0
    29 sg:pub.10.1186/1477-7525-2-12
    30 sg:pub.10.1186/1745-6215-10-113
    31 schema:datePublished 2011-04-06
    32 schema:datePublishedReg 2011-04-06
    33 schema:description Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.IntroductionNon-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.MethodsData from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.ResultsMedian TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).ConclusionsLower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up.
    34 schema:genre article
    35 schema:inLanguage en
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N35fc49e1246e4b52b2d651a56ba950d0
    38 Na879a11d307047e3b272930352893e73
    39 sg:journal.1100834
    40 schema:keywords MethodsData
    41 Prospective Observational Scientific Study
    42 TSQM scores
    43 Treatment Satisfaction Questionnaire
    44 adherence
    45 association
    46 behavior
    47 bisphosphonates
    48 cohort study
    49 compliance
    50 data
    51 discontinuation/
    52 discontinuation/switching
    53 domain
    54 effect
    55 effect severity
    56 entry
    57 experience study
    58 follow
    59 global satisfaction
    60 global satisfaction domains
    61 greater treatment satisfaction
    62 hazard ratio
    63 hazards regression
    64 high satisfaction
    65 instruction
    66 lifestyle behaviors
    67 logistic regression
    68 longitudinal cohort study
    69 lower satisfaction
    70 lower scores
    71 lower treatment satisfaction
    72 median score
    73 medication adherence
    74 medications
    75 osteoporosis medication adherence
    76 osteoporosis medications
    77 osteoporosis therapy
    78 participants
    79 patient-reported data
    80 period
    81 persistence
    82 possible uses
    83 postmenopausal women
    84 proportional hazards regression
    85 questionnaire
    86 ratio
    87 regression
    88 relationship
    89 results
    90 risk
    91 satisfaction
    92 satisfaction domains
    93 satisfaction questionnaire
    94 scientific studies
    95 scores
    96 severe side effects
    97 severity
    98 side effect severity
    99 side effects
    100 study
    101 study entry
    102 switching
    103 therapy
    104 treatment satisfaction
    105 uses
    106 women
    107 years
    108 schema:name Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™
    109 schema:pagination 733-741
    110 schema:productId N464e4d0d097f41119b48a488e04a1c4d
    111 N4da6688c29444188bbaf8d82dceb4e87
    112 N783988cb7eb94a82adeb175c1214a0f8
    113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049583566
    114 https://doi.org/10.1007/s00198-011-1620-3
    115 schema:sdDatePublished 2022-05-20T07:27
    116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    117 schema:sdPublisher N04596d0c742243dabaa2ac5fba3be925
    118 schema:url https://doi.org/10.1007/s00198-011-1620-3
    119 sgo:license sg:explorer/license/
    120 sgo:sdDataset articles
    121 rdf:type schema:ScholarlyArticle
    122 N03c4ecfa1018472da54b6ea79dd15670 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Middle Aged
    124 rdf:type schema:DefinedTerm
    125 N03dcc83b90cd4b58ad5f3f4621aab1fc schema:affiliation grid-institutes:grid.417886.4
    126 schema:familyName Stewart
    127 schema:givenName R.
    128 rdf:type schema:Person
    129 N04596d0c742243dabaa2ac5fba3be925 schema:name Springer Nature - SN SciGraph project
    130 rdf:type schema:Organization
    131 N0ebcf9e1f4e741a1811d4431b13b9313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Humans
    133 rdf:type schema:DefinedTerm
    134 N217305304fad448980a9922e45202bc6 rdf:first sg:person.01262457746.85
    135 rdf:rest N9cf60dd727dc43cbbb3c25dac524877f
    136 N2337e74daf1f45b4ab4934c627b56bdc rdf:first sg:person.0617012057.00
    137 rdf:rest N653d4a97ce0941578f53f38c3f2da0dd
    138 N269e2e5ffd3747718a7a65f32857a4ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Epidemiologic Methods
    140 rdf:type schema:DefinedTerm
    141 N2f456adc52694788a76261f2a94b1bb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Female
    143 rdf:type schema:DefinedTerm
    144 N35fc49e1246e4b52b2d651a56ba950d0 schema:issueNumber 2
    145 rdf:type schema:PublicationIssue
    146 N45cfa34dba0d4594bf27fc8e4e82b80f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Osteoporosis, Postmenopausal
    148 rdf:type schema:DefinedTerm
    149 N464e4d0d097f41119b48a488e04a1c4d schema:name pubmed_id
    150 schema:value 21625886
    151 rdf:type schema:PropertyValue
    152 N4da6688c29444188bbaf8d82dceb4e87 schema:name doi
    153 schema:value 10.1007/s00198-011-1620-3
    154 rdf:type schema:PropertyValue
    155 N63ec79ec89b9494babd25b711978c3d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Bone Density Conservation Agents
    157 rdf:type schema:DefinedTerm
    158 N6422f536099f4c93b17f4f9bb5973d26 rdf:first sg:person.01346631166.35
    159 rdf:rest N2337e74daf1f45b4ab4934c627b56bdc
    160 N653d4a97ce0941578f53f38c3f2da0dd rdf:first sg:person.0733051777.39
    161 rdf:rest N217305304fad448980a9922e45202bc6
    162 N6eb32962c01b4e1f819323db0744cdb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Patient Satisfaction
    164 rdf:type schema:DefinedTerm
    165 N783988cb7eb94a82adeb175c1214a0f8 schema:name dimensions_id
    166 schema:value pub.1049583566
    167 rdf:type schema:PropertyValue
    168 N9cf60dd727dc43cbbb3c25dac524877f rdf:first N03dcc83b90cd4b58ad5f3f4621aab1fc
    169 rdf:rest Nabfedd67f5484bb0b364e25dd1509d32
    170 Na879a11d307047e3b272930352893e73 schema:volumeNumber 23
    171 rdf:type schema:PublicationVolume
    172 Na9bb60b9411e4dd79ddd04d80630f743 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Osteoporotic Fractures
    174 rdf:type schema:DefinedTerm
    175 Nabfedd67f5484bb0b364e25dd1509d32 rdf:first sg:person.01151363702.27
    176 rdf:rest Nc5b0649e88bc48d7959f77c2b8ed281e
    177 Nb7bab3fef41844bf8b82e1ac14a5a3dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name United States
    179 rdf:type schema:DefinedTerm
    180 Nc392fd3d8504459db709ffb07a890b75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Medication Adherence
    182 rdf:type schema:DefinedTerm
    183 Nc5b0649e88bc48d7959f77c2b8ed281e rdf:first sg:person.0652405653.55
    184 rdf:rest rdf:nil
    185 Ncb2bcd660c874831950e0f9a413e28ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Diphosphonates
    187 rdf:type schema:DefinedTerm
    188 Nd1dd8dac6391443eaec3bd0b32896807 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Primary Health Care
    190 rdf:type schema:DefinedTerm
    191 Nd5d59f5afb4845b58e70b75c4ff9015b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Aged
    193 rdf:type schema:DefinedTerm
    194 Ndffff3838d504e5bb68d681e2269ab44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Treatment Outcome
    196 rdf:type schema:DefinedTerm
    197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    198 schema:name Medical and Health Sciences
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Clinical Sciences
    202 rdf:type schema:DefinedTerm
    203 sg:journal.1100834 schema:issn 0937-941X
    204 1433-2965
    205 schema:name Osteoporosis International
    206 schema:publisher Springer Nature
    207 rdf:type schema:Periodical
    208 sg:person.01151363702.27 schema:affiliation grid-institutes:grid.417886.4
    209 schema:familyName Gao
    210 schema:givenName G.
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151363702.27
    212 rdf:type schema:Person
    213 sg:person.01262457746.85 schema:affiliation grid-institutes:grid.417886.4
    214 schema:familyName Satram-Hoang
    215 schema:givenName S.
    216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262457746.85
    217 rdf:type schema:Person
    218 sg:person.01346631166.35 schema:affiliation grid-institutes:grid.266100.3
    219 schema:familyName Barrett-Connor
    220 schema:givenName E.
    221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346631166.35
    222 rdf:type schema:Person
    223 sg:person.0617012057.00 schema:affiliation grid-institutes:None
    224 schema:familyName Wade
    225 schema:givenName S. W.
    226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
    227 rdf:type schema:Person
    228 sg:person.0652405653.55 schema:affiliation grid-institutes:grid.417886.4
    229 schema:familyName Macarios
    230 schema:givenName D.
    231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652405653.55
    232 rdf:type schema:Person
    233 sg:person.0733051777.39 schema:affiliation grid-institutes:grid.417886.4
    234 schema:familyName Do
    235 schema:givenName T. P.
    236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39
    237 rdf:type schema:Person
    238 sg:pub.10.1007/bf03324587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038551591
    239 https://doi.org/10.1007/bf03324587
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1007/s00198-002-1370-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021711183
    242 https://doi.org/10.1007/s00198-002-1370-3
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1007/s00198-004-1818-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019683703
    245 https://doi.org/10.1007/s00198-004-1818-8
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
    248 https://doi.org/10.1007/s00198-006-0073-6
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1007/s00198-006-0166-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034510225
    251 https://doi.org/10.1007/s00198-006-0166-2
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1007/s00198-008-0674-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041206509
    254 https://doi.org/10.1007/s00198-008-0674-3
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1007/s00198-009-0976-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025143605
    257 https://doi.org/10.1007/s00198-009-0976-0
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1007/s00198-009-1023-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034744843
    260 https://doi.org/10.1007/s00198-009-1023-x
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1007/s00198-009-1133-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042711530
    263 https://doi.org/10.1007/s00198-009-1133-5
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1007/s00198-009-1134-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021804673
    266 https://doi.org/10.1007/s00198-009-1134-4
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1007/s11606-008-0772-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029719812
    269 https://doi.org/10.1007/s11606-008-0772-0
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1186/1477-7525-2-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039428500
    272 https://doi.org/10.1186/1477-7525-2-12
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1186/1745-6215-10-113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051078892
    275 https://doi.org/10.1186/1745-6215-10-113
    276 rdf:type schema:CreativeWork
    277 grid-institutes:None schema:alternateName Wade Outcomes Research and Consulting, Salt Lake City, UT, USA
    278 schema:name Wade Outcomes Research and Consulting, Salt Lake City, UT, USA
    279 rdf:type schema:Organization
    280 grid-institutes:grid.266100.3 schema:alternateName Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA
    281 schema:name Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0607, La Jolla, CA, USA
    282 rdf:type schema:Organization
    283 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., Thousand Oaks, CA, USA
    284 schema:name Amgen Inc., Thousand Oaks, CA, USA
    285 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...